S-3 GROUP

Lobbying for AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. · Biopharmaceutical development

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Illinois · House · Senate · $60,000.00 income · posted Jan 16, 2026

Bills named in this filing 2

Lobbying activity 2

Health Issues

H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019

Budget/Appropriations

Issues related to health care research

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.